Denmark Proposes Making Its Medical Cannabis Program Permanent

Denmark plans to make its pilot medical cannabis program permanent following its success in treating severe symptoms like chronic pain and chemotherapy-induced nausea for approximately 1,800 patients. The proposal, supported by safety evaluations and legalized local cultivation since 2021, will be discussed with key political parties to secure long-term patient access beyond 2025.

The government in Denmark has announced its intention to make its pilot medical cannabis program permanent. This decision, spearheaded by Interior and Health Minister Sophie Løhde, reflects the growing acceptance and demand for cannabis-based treatments among patients with severe illnesses.

For more news like this, along with all the latest in legalization, research, and lifestyle, download our free cannabis news app.

Promising Results From the Denmark Pilot Program

Introduced in 2018, the pilot medical cannabis program in Denmark was designed to provide a legal pathway for specific patient groups — including those with multiple sclerosis, spinal cord injuries, chronic pain, or undergoing chemotherapy — to access cannabis as part of their treatment plans. Over the past three years, the program has seen significant growth, with more than 20,000 prescriptions issued, according to a recent evaluation.

The evaluation highlights that approximately 1,800 patients in Denmark are currently benefiting from cannabis-based medications. These treatments often target severe symptoms, such as chronic pain and chemotherapy-induced nausea, for which traditional medications have provided insufficient relief.

Minister Løhde noted the tangible benefits reported by patients:

“We can see that many patients whose doctors have prescribed medical cannabis seem to benefit from the treatment. This includes cancer patients suffering from severe nausea after chemotherapy or people with multiple sclerosis experiencing intense pain.”

Monitoring the Program in Denmark

The Danish Medicines Agency has closely monitored the program in Denmark, ensuring no significant safety concerns have arisen during its implementation. The findings bolster the idea that medical cannabis can be a safe therapeutic option for many patients when prescribed and monitored appropriately.

In 2021, the Denmark pilot program was extended for four years, accompanied by a major milestone: the permanent legalization of cannabis cultivation for medical purposes in Denmark. This measure supports local production and ensures a stable supply of high-quality medical cannabis. Denmark has also become a hub for several European cannabis companies, including Bedrocan and Canopy Growth, since 2017.

Next Steps Toward Permanency

The government’s proposal to make the program permanent will now be discussed with political parties, including the Socialist People’s Party (SF), the Liberal Alliance, the Red-Green Alliance (Enhedslisten), the Danish People’s Party (Dansk Folkeparti), and The Alternative (Alternativet). These discussions will determine whether the Denmark program transitions from a pilot initiative to a long-term healthcare policy.

If approved, this decision will secure legal access to medical cannabis for patients in Denmark beyond the program’s scheduled conclusion in 2025.

—

(Featured image by Markus Winkler via Pexels)

DISCLAIMER: This article was written by a third-party contributor and does not reflect the opinion of Hemp.im, its management, staff, or its associates. Please review our disclaimer for more information.

This article may include forward-looking statements. These forward-looking statements generally are identified by the words “believe,” “project,” “estimate,” “become,” “plan,” “will,” and similar expressions. These forward-looking statements involve known and unknown risks as well as uncertainties, including those discussed in the following cautionary statements and elsewhere in this article and on this site. Although the company may believe that its expectations are based on reasonable assumptions, the actual results that the company may achieve may differ materially from any forward-looking statements, which reflect the opinions of the management of the company only as of the date hereof. Additionally, please make sure to read these important disclosures.

First published in Newsweed, a third-party contributor translated and adapted the article from the original. In case of discrepancy, the original will prevail.

Although we made reasonable efforts to provide accurate translations, some parts may be incorrect. Hemp.im assumes no responsibility for errors, omissions or ambiguities in the translations provided on this website. Any person or entity relying on translated content does so at their own risk. Hemp.im is not responsible for losses caused by such reliance on the accuracy or reliability of translated information. If you wish to report an error or inaccuracy in the translation, we encourage you to contact us.